drugset / Trial / NCT00151398

Study Evaluating Lecozotan SR in Mild to Moderate Alzheimer's Disease (AD)

NCT00151398

Phase 2 Completed 229 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is determine the safety, tolerability, and efficacy of 3 doses of lecozotan SR in patients with mild to moderate Alzheimer's Disease over 12 weeks.

Timeline

Start
2005-10-06
Primary completion
2008-03-15
Completion
2008-03-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Donepezil Small molecule 10 mg
Subject Lecozotan Small molecule 2 mg
Subject Lecozotan Small molecule 5 mg
Subject Lecozotan Small molecule 10 mg

Indications